Promimic AB (publ) (PRO.ST)
SEK 25.8
(-1.15%)
SEK 25.8
(-1.15%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 92.87 Million SEK | 0.11% |
| 2022 | 92.77 Million SEK | 188.45% |
| 2021 | 32.16 Million SEK | -27.8% |
| 2020 | 44.54 Million SEK | 36.82% |
| 2019 | 32.56 Million SEK | 33.15% |
| 2018 | 24.45 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 81.99 Million SEK | -5.36% |
| 2024 Q1 | 86.64 Million SEK | -6.71% |
| 2023 Q2 | 87.49 Million SEK | -0.35% |
| 2023 FY | 92.87 Million SEK | 0.11% |
| 2023 Q4 | 92.87 Million SEK | 8.71% |
| 2023 Q3 | 85.43 Million SEK | -2.36% |
| 2023 Q1 | 87.8 Million SEK | -5.36% |
| 2022 Q2 | 98.7 Million SEK | 238.39% |
| 2022 Q4 | 92.77 Million SEK | 2.46% |
| 2022 Q3 | 90.54 Million SEK | -8.26% |
| 2022 FY | 92.77 Million SEK | 188.45% |
| 2022 Q1 | 29.16 Million SEK | -9.31% |
| 2021 Q4 | 32.16 Million SEK | -0.57% |
| 2021 Q3 | 32.34 Million SEK | -11.39% |
| 2021 FY | 32.16 Million SEK | -27.8% |
| 2021 Q2 | 36.5 Million SEK | -11.43% |
| 2021 Q1 | 41.21 Million SEK | 0.0% |
| 2020 FY | 44.54 Million SEK | 36.82% |
| 2019 FY | 32.56 Million SEK | 33.15% |
| 2018 FY | 24.45 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | -47.693% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 97.175% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 97.175% |
| Arcoma AB | 81.96 Million SEK | -13.315% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | 86.399% |
| BICO Group AB (publ) | 10.19 Billion SEK | 99.089% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | 87.7% |
| CellaVision AB (publ) | 928.71 Million SEK | 90.0% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | -60.892% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -323.015% |
| C-Rad AB (publ) | 404 Million SEK | 77.011% |
| Duearity AB (publ) | 15.14 Million SEK | -513.279% |
| Dignitana AB (publ) | 44.83 Million SEK | -107.167% |
| Episurf Medical AB (publ) | 104.3 Million SEK | 10.954% |
| Getinge AB (publ) | 55.09 Billion SEK | 99.831% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | 9.512% |
| Iconovo AB (publ) | 128.07 Million SEK | 27.487% |
| Integrum AB (publ) | 164.85 Million SEK | 43.664% |
| Luxbright AB (publ) | 40.68 Million SEK | -128.269% |
| Mentice AB (publ) | 322.52 Million SEK | 71.204% |
| OssDsign AB (publ) | 356.38 Million SEK | 73.94% |
| Paxman AB (publ) | 167.12 Million SEK | 44.428% |
| Qlife Holding AB (publ) | 39.04 Million SEK | -137.86% |
| SciBase Holding AB (publ) | 64.33 Million SEK | -44.364% |
| ScandiDos AB (publ) | 81.47 Million SEK | -13.995% |
| Sectra AB (publ) | 3.21 Billion SEK | 97.108% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | 90.841% |
| Senzime AB (publ) | 433.54 Million SEK | 78.578% |
| SpectraCure AB (publ) | 144.83 Million SEK | 35.875% |
| Stille AB | 804.89 Million SEK | 88.461% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 99.433% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 95.77% |